MSCV_Cas9_puro Citations (16)
Originally described in: Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains.Shi J, Wang E, Milazzo JP, Wang Z, Kinney JB, Vakoc CR Nat Biotechnol. 2015 May 11. doi: 10.1038/nbt.3235. PubMed Journal
Articles Citing MSCV_Cas9_puro
| Articles |
|---|
Rapid generation of drug-resistance alleles at endogenous loci using CRISPR-Cas9 indel mutagenesis.
Ipsaro JJ, Shen C, Arai E, Xu Y, Kinney JB, Joshua-Tor L, Vakoc CR, Shi J.
PLoS One. 2017 Feb 23;12(2):e0172177. doi: 10.1371/journal.pone.0172177. eCollection 2017.
PubMed
Associated Plasmids |
| A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia. Pardee TS, Anderson RG, Pladna KM, Isom S, Ghiraldeli LP, Miller LD, Chou JW, Jin G, Zhang W, Ellis LR, Berenzon D, Howard DS, Hurd DD, Manuel M, Dralle S, Lyerly S, Powell BL. Clin Cancer Res. 2018 May 1;24(9):2060-2073. doi: 10.1158/1078-0432.CCR-17-2282. Epub 2018 Feb 6. PubMed |
Engagement of DNA and H3K27me3 by the CBX8 chromodomain drives chromatin association.
Connelly KE, Weaver TM, Alpsoy A, Gu BX, Musselman CA, Dykhuizen EC.
Nucleic Acids Res. 2018 Dec 29. pii: 5266947. doi: 10.1093/nar/gky1290.
PubMed
Associated Plasmids |
| Targeting an RNA-Binding Protein Network in Acute Myeloid Leukemia. Wang E, Lu SX, Pastore A, Chen X, Imig J, Chun-Wei Lee S, Hockemeyer K, Ghebrechristos YE, Yoshimi A, Inoue D, Ki M, Cho H, Bitner L, Kloetgen A, Lin KT, Uehara T, Owa T, Tibes R, Krainer AR, Abdel-Wahab O, Aifantis I. Cancer Cell. 2019 Mar 18;35(3):369-384.e7. doi: 10.1016/j.ccell.2019.01.010. Epub 2019 Feb 21. PubMed |
| The E3 ubiquitin ligase SPOP controls resolution of systemic inflammation by triggering MYD88 degradation. Guillamot M, Ouazia D, Dolgalev I, Yeung ST, Kourtis N, Dai Y, Corrigan K, Zea-Redondo L, Saraf A, Florens L, Washburn MP, Tikhonova AN, Malumbres M, Gong Y, Tsirigos A, Park C, Barbieri C, Khanna KM, Busino L, Aifantis I. Nat Immunol. 2019 Sep;20(9):1196-1207. doi: 10.1038/s41590-019-0454-6. Epub 2019 Aug 12. PubMed |
Genetic modification of primary human B cells to model high-grade lymphoma.
Caeser R, Di Re M, Krupka JA, Gao J, Lara-Chica M, Dias JML, Cooke SL, Fenner R, Usheva Z, Runge HFP, Beer PA, Eldaly H, Pak HK, Park CS, Vassiliou GS, Huntly BJP, Mupo A, Bashford-Rogers RJM, Hodson DJ.
Nat Commun. 2019 Oct 4;10(1):4543. doi: 10.1038/s41467-019-12494-x.
PubMed
Associated Plasmids |
| Gene Editing in B-Lymphoma Cell Lines Using CRISPR/Cas9 Technology. Bai B, Myklebust JH, Walchli S. Methods Mol Biol. 2020;2115:445-454. doi: 10.1007/978-1-0716-0290-4_25. PubMed |
| Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer. Vatapalli R, Sagar V, Rodriguez Y, Zhao JC, Unno K, Pamarthy S, Lysy B, Anker J, Han H, Yoo YA, Truica M, Chalmers ZR, Giles F, Yu J, Chakravarti D, Carneiro B, Abdulkadir SA. Nat Commun. 2020 Aug 19;11(1):4153. doi: 10.1038/s41467-020-18013-7. PubMed |
| Valine tRNA levels and availability regulate complex I assembly in leukaemia. Thandapani P, Kloetgen A, Witkowski MT, Glytsou C, Lee AK, Wang E, Wang J, LeBoeuf SE, Avrampou K, Papagiannakopoulos T, Tsirigos A, Aifantis I. Nature. 2022 Jan;601(7893):428-433. doi: 10.1038/s41586-021-04244-1. Epub 2021 Dec 22. PubMed |
| Adenosine Monophosphate Activated Protein Kinase (AMPK) enhances chemotherapy response in Acute Myeloid Leukemia (AML). Ghiraldeli L, Anderson R, Pladna K, Pardee TS. Cancer Lett. 2022 Jun 1;535:215659. doi: 10.1016/j.canlet.2022.215659. Epub 2022 Mar 20. PubMed |
| Phase II trial of cytarabine and mitoxantrone with devimistat in acute myeloid leukemia. Anderson R, Miller LD, Isom S, Chou JW, Pladna KM, Schramm NJ, Ellis LR, Howard DS, Bhave RR, Manuel M, Dralle S, Lyerly S, Powell BL, Pardee TS. Nat Commun. 2022 Mar 30;13(1):1673. doi: 10.1038/s41467-022-29039-4. PubMed |
| TCF-1 promotes chromatin interactions across topologically associating domains in T cell progenitors. Wang W, Chandra A, Goldman N, Yoon S, Ferrari EK, Nguyen SC, Joyce EF, Vahedi G. Nat Immunol. 2022 Jul;23(7):1052-1062. doi: 10.1038/s41590-022-01232-z. Epub 2022 Jun 20. PubMed |
| Mechanism of CD79A and CD79B Support for IgM+ B Cell Fitness through B Cell Receptor Surface Expression. Huse K, Bai B, Hilden VI, Bollum LK, Vatsveen TK, Munthe LA, Smeland EB, Irish JM, Walchli S, Myklebust JH. J Immunol. 2022 Nov 15;209(10):2042-2053. doi: 10.4049/jimmunol.2200144. PubMed |
| Extracellular Galectin 4 Drives Immune Evasion and Promotes T-cell Apoptosis in Pancreatic Cancer. Lidstrom T, Cumming J, Gaur R, Frangsmyr L, Pateras IS, Mickert MJ, Franklin O, Forsell MNE, Arnberg N, Dongre M, Patthey C, Ohlund D. Cancer Immunol Res. 2023 Jan 3;11(1):72-92. doi: 10.1158/2326-6066.CIR-21-1088. PubMed |
| Pyruvate Dehydrogenase Inhibition Leads to Decreased Glycolysis, Increased Reliance on Gluconeogenesis and Alternative Sources of Acetyl-CoA in Acute Myeloid Leukemia. Anderson R, Pladna KM, Schramm NJ, Wheeler FB, Kridel S, Pardee TS. Cancers (Basel). 2023 Jan 12;15(2):484. doi: 10.3390/cancers15020484. PubMed |
| ALPL-1 is a target for chimeric antigen receptor therapy in osteosarcoma. Mensali N, Koksal H, Joaquina S, Wernhoff P, Casey NP, Romecin P, Panisello C, Rodriguez R, Vimeux L, Juzeniene A, Myhre MR, Fane A, Ramirez CC, Maggadottir SM, Duru AD, Georgoudaki AM, Grad I, Maturana AD, Gaudernack G, Kvalheim G, Carcaboso AM, de Alava E, Donnadieu E, Bruland OS, Menendez P, Inderberg EM, Walchli S. Nat Commun. 2023 Jun 8;14(1):3375. doi: 10.1038/s41467-023-39097-x. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.